Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social ...
Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics ...
MEDICATIONS taken by thousands of Brits for to treat an overactive bladder have been linked to dementia in a new study. Some forms of the medication have been found to raise the risk of dementia ...